InMed Updated Check List: Updated Check List:
Investing in InMed is like owning a biotech hedge fund full of organic therapies and delivery systems, run by a growing list of world renowned scientists.
InMed expects to add 5 to 9 new assets in 2015 in important target areas like breast cancer, obesity, diabetes and epilepsy to name a few.
InMeds IDP bioinformatics based platform, coupled with their innovative drug delivery system anticipates an accelerated pathway to commercialization in as little as 3 years.
InMed will have 12 PHD's, 6 M.Sc.'s and 5 lab technicians during their 2015 pre-clinical and clinical trials at 2 departments on the UBC campus.
Research also taking place at the University of Debrecen, 2 hours out of Budapest, Hungary
10 month (Updated) Conclusion Check List:
- Health Canada approves InMed's application for an exemption under Section 56 of the Controlled Drugs and Substances Act? Check.
- Awarded Mitacs grant that will be utilized to screen selected InMed compounds in orofacial pain models? Check.
- CMO (former Associate Medical Director of GW Pharmaceuticals) with global expertise in regulatory affairs, clinical development and marketing in cannabinoid based therapies? Check.
- Announces an exclusive strategic collaboration with the University of Debrecen, Hungary, to develop novel phytocannabinoid-based therapies to treat ocular allergic symptoms, led by one of the world's leading (Professor Tamas Biro researches for GW Pharmaceuticals as well) cannabinoid researchers? Check.
-In house senior bioinformatician enabling the Company to discover novel cannabis based drug therapies to add to growing therapy pipeline? Check.
- Retains Tiberend Strategic Advisors (New York) to manage its investor and corporate communications programs? Check.
- World renowned scientific team with multidisciplinary expertise? Check.
- CSO who has a track record that developed several drugs over 15 years, generating over $500m in revenues? Check
- Global organizations, governments, and big pharma companies that have previously benefitted from the teams research? Check.
- Proprietary Intelligent Cannabinoid Drug Design Platform (IDP) Check.
- Tools to isolate and identify chemical compounds both quickly and effectively? Check.
- In-house Breeding, Genetics and Cultivation division? Check.
- Capable of developing compounds for therapies in months rather than years? Check.
- Target specific diseases and conditions? Check.
- Outsource early-stage research and trials to conserve capital? Check.
- Fast Forward through Phase I, Phase II & Phase III quickly and inexpensively compared to traditional Pharma? Check
- Competitive edge from companies that rely on third-parties to manufacture their treatments? Check
- Fully-integrated operations to lower costs and increase quality? Check
- Capable of commercializing therapies in a 1/3 the time of traditional drug development? Check.
- Analogous company with a $2 billion market cap? Check
- Developing medicines for:
- Glaucoma
- Pain and Inflammation
- Orphan Diseases
- Metabolic Disease (Obesity, Diabetes)
- Cancers and Metabolic Diseases? Check.
Major pharmaceuticals involved in cannabinoid R & D and commercialization include:
Biogen Idec (Market Cap: $97 Billion)
Novartis (MC: $235 B)
Lilly (MC: $74B)
Bayer (MC: $112 B)
Sanofi (MC: $125 B)
Otsuka (MC: $17B)
Ipsen (MC: $3.7 B)
Almirall (MC:$2.31B)
GW Pharma (MC: $1.6B)
Neopharm (MC: $263 Mil)
Cambridge Isotope Laboratories (N/A)
United Pharma (N/A)
"To my way of thinking, you’ll rarely go broke investing in the brightest minds in the business, and the pointy heads at InMed have something that costs them next to nothing to run, can be licensed out to researchers all over the world, and could rapidly become a clearinghouse for CBD biotech IP."
"Let me put it in layman’s terms. InMed has a software platform that, in essence, goes through reams of approved drug therapies, breaks down the elements within them, and then looks for similar elements in cannabinoids. As a hypothetical, let’s say Pfizer has a Parkinson’s Disease treatment that they’ve spent seven years and $100m getting FDA approval. Well played to them, but along comes InMed, finds the active ingredient in that drug is also found in Purple Head Explosion Kush #42, InMed isolates that ingredient and – ta-da – you’ve got a potential new therapy that breaks no patents and can be moved to market ultra-fast because it's already okayed by the FDA."
---Chris Parry March 11, 2015
<br> <br> <a href="https://www.stockhouse.com/news/newswire/2015/03/10/medical-marijuana-update-inmed-c-in-builds-on-300-upswing-with-new-partner" class="BBLink" rel="noindex nofollow" target="_blank">https://www.stockhouse.com/news/newswire/2015/03/10/medical-marijuana-update-inmed-c-in-builds-on-300-upswing-with-new-partner</a><br> <br>
All Natural: The Opportunity In Pharmaceutical Cannabinoid Medicine With InMed Pharmaceuticals Inc.
<br> <br> <a href="https://seekingalpha.com/instablog/27523743-point-of-return/3789506-all-natural-the-opportunity-in-pharmaceutical-cannabinoid-medicine-with-inmed-pharmaceuticals-inc" class="BBLink" rel="noindex nofollow" target="_blank">https://seekingalpha.com/instablog/27523743-point-of-return/3789506-all-natural-the-opportunity-in-pharmaceutical-cannabinoid-medicine-with-inmed-pharmaceuticals-inc</a><br> <br>
<br><a href="https://www.inmedpharma.com/s/home.asp" class="BBLink" rel="noindex nofollow" target="_blank">https://www.inmedpharma.com/s/home.asp</a><br> <br>
July 25th "46 Reasons" report:
<br> <br> <a href="https://www.stockhouse.com/companies/bullboard/c.in/inmed-pharmaceuticals-inc?postid=22781425
" class="BBLink" rel="noindex nofollow" target="_blank">https://www.stockhouse.com/companies/bullboard/c.in/inmed-pharmaceuticals-inc?postid=22781425
</a><br> <br>
46 Reasons why Cannabis Technologies (inMed) will Succeed
1) Investing in biotech can be extremely challenging. There is always a chance that someone will come out with a better product. Typically, it takes a decade or more to approval, followed by commercialization. It usually costs tens of millions, to billions of dollars per drug. This can be highly dilutive to a small startup.
2) What if one company had a proprietary cookie cutter system targeting a dozen diseases quicker, cheaper and more effective? I am not sure what Cannabis Technologies will be called in a year from now. I think it will have a new name... perhaps GW Pharmaceuticals or Eli Lily? Or Novartis?
3) Dr. Hossain was chiefly responsible for a $157 million deal with Novartis a decade ago. There was also a $376 million deal with Teva in 2012 based on one of his discoveries. More on that later.
4) Dr. Tarek Mansour (Pfizer) was responsible for multiple FDA approved drugs, where the market value exceeded $1 billion. (Zeffix, Troxatyl, Bosulif, Neratinib and PFE384)
5) The big question is...how many therapy product launches, and strategic partnerships will it take before Big Pharma catches on?
6) The amplitude of possibilities dictates that Cannabis Technologies will one day be a dominant player in the prescription cannabinoid medicine market.
7) Many people now know there are at least 85 different cannabinoids isolated from cannabis exhibiting various effects that could prove therapeutic.
8) They also know that cannabidiol (CBD) alone has shown therapeutic benefits to at least 16 diseases.
9) CAN will take advantage of Strain differences to develop drugs for specific diseases, including:
Glaucoma, Inflammation/Pain/Arthritis, Huntington's, Epilepsy, Diabetes, Obesity, Cancer & Angiogenesis
10) CAN's proprietary Cannabinoid Drug Design Platform ("CDP") allows computer science, statistics, mathematics and engineering to study biological data and processes from the cannabis plant which can be targeted to develop therapies for specific diseases and conditions.
11) What will CAN's CDP be worth to a company that wants to compete with GWPH...or a better question..what would it be worth to GWPH?
12) The main active ingredients in this are the cannabinoids THC and CBD, but other pharmacologically active cannabinoids are also present and are being investigated.
13) This Platform Technology, combined with CAN's world renowned scientific team, will enable the company to discover therapies based on proven genomics and unique chemical fingerprints that specific cellular processes leave behind.
14) They will do this both quickly and effectively, with very little money, by outsourcing patented products that are ready for clinical trials and allow a company like Novartis (for example) to absorb all the costs through to commercialization. CAN will retain a fair and reasonable interest that may generate substantial revenue.
Track Record
Dr. Hossain's successful financial deals based on his drug discoveries over the last 15 years include:
15) 2004: Xenon, Novartis Enter $157M Deal For Obesity Compounds
16) 2006: Xenon and Takeda Announce $75M Agreement To Develop and Commercialize XEN401 for Pain
17) 2006: Xenon Enters Into Anemia Collaboration With Roche ($7 Million for Equity, and $44 Million From Research Funding)
18) 2012: Teva inks $376M deal on Xenon pain program
19) 2009: YM Biosciences Collaboration with the National Research Council of Canada’s Biotechnology Research Institute (NRC-BRI) yielded novel anticancer antibodies that may be safer than similar drugs sold by Genentech/Roche. (another partnership resulted in the production of new breast cancer drug candidates.)
20) 2009: NRC-BRI granted Alethia Biotherapeutics exclusive, worldwide diagnostic rights to a peptide that specifically binds to tumor-associated clusterin in cancer patients.
Who should CAN target?
21) GW Pharmaceuticals has one the broadest clinical pipelines of any company in the marijuana industry...so will CAN.
22) Even though GW may be suffering the typical challenges that all biopharma companies have to endure, with costs far outstripping revenues, they had no problem raising $169.8 million last month.
23) Over 30 years ago, two young men made their way to Vancouver from Seattle to raise money for their software company, and were unfortunately turned down. Their names were Bill Gates and Paul Allen. Very few understood what they had.
24) I think CAN is in the same position today, however, that is changing with Chris Parry writing one of the first articles. Cancer survivor and canabis acdvocate Cheryl Shuman recently endorsed Cannabis Technologies as well.
25) If the billionaire activists want Marijuana to be legalized they most likely would want to facilitate the fast tracking of several revolutionary therapies that will indeed improve the lives of the millions of sufferers around the world.
26) George Soros has spent at least $80 million on the legalization effort since 1994.
27) The late Peter B. Lewis, channeled more than $40 million to influence local debates.
28) The two billionaires’ funding has been unmatched by anyone.
29) Other wealthy activists include: Google billionaire Paul Buchheit, Facebook forefathers Sean Parker and Dustin Moskovitz, and Men’s Wearhouse founder George Zimmer.
30) As of March 31, GWPH had 75 Institutional Holders (sooner or later, they will know about CAN)
31) Analyst Firms Making GWPH Recommendations: Bank of America, Cowen, Piper Jaffray, Leerink Swann, and Morgan Stanley.
Conclusion Check List:
32) World renowned scientific team with multidisciplinary expertise? Check.
33) CSO who has a track record that developed several drugs over 15 years, generating over $500m in revenues? Check
34) Global organizations, governments, and big pharma companies that have previously benefitted from the teams research? Check.
35) Proprietary Cannabinoid Drug Design Platform? Check.
36) Tools to isolate and identify chemical compounds both quickly and effectively? Check.
37) In-house Breeding, Genetics and Cultivation division? Check.
38) Capable of developing compounds for therapies in months rather than years? Check.
39) Target specific diseases and conditions? Check.
40) Outsource early-stage research and trials to conserve capital? Check.
41) Fast Forward through Phase I, Phase II & Phase III quickly and inexpensively compared to traditional Pharma? Check
42) Competitive edge from companies that rely on third-parties to manufacture their treatments? Check
43) Fully-integrated operations to lower costs and increase quality? Check
44) Capable of commercializing therapies in a 1/3 the time of traditional drug development? Check.
45) Anaglous company with a $1.5b market cap? Check
46) Developing medicines for:
- Glaucoma
- Pain and Inflammation
- Orphan Diseases
- Metabolic Disease (Obesity, Diabetes)
- Cancers and Metabolic Diseases? Check.
Dr. Sazzad Hossain, Ph.D., M.Sc.
Chief Scientific Officer
- 20 years of academic and industrial experience in new drug discovery, natural health product development
- Group Leader and Senior Scientist at Biotechnology Research Institute of National Research Council Canada, Government of Canada's prime biotechnology research organization where he set up pharmacology laboratory to evaluate safety and efficacy of new drugs under development in the areas of cancer, cardiovascular and ocular diseases.
Dr. Tarek S. Mansour, Ph.D., M.Sc.
Scientific Advisor
- Dr. Mansour was responsible for transition of staff and projects to the Pfizer pipeline
-Founder and Chief Executive Officer of Sabila Biosciences LLC, New York
- Under his leadership, several compounds have progressed to various stages of clinical evaluation including FDA approvals and late stage development including: Zeffix, Troxatyl, Bosulif, Neratinib and PFE384.
Dr. Hyder A. Khoja, Ph.D., M.Sc., A.Ag.
Director of Botanical Research and Cultivation
- 17 years of extensive experience in a broad range of life sciences and business services with strong leadership combined with functional expertise and experience in general business management
- Industry experience spans from initiation, operation, and contribution towards developing several research and business proposals in the fields of Agriculture-Food Security, Food Safety & Sovereignty, Alternative energy, Renewable resources, Biofuels, Nutraceutical, Hydroponics, Agriculture & Land use management and Technology transfer
- Presented his work both in at federal government and academic institutions with authorship in over 18 peer-reviewed papers, primarily in genomics, plant physiology, and alternative energy.
-His work was also recognized and appeared in United Nations Food and Agriculture Organization (FAO) Environment and Natural Resources Management as a working paper for Algae-based Biofuels
Craig Schneider
One of Craig's first companies that he worked for was Ultra Petroleum. The stock dropped from .95 to .45 before blasting through the stratosphere to a stunning pre split price of close to $200. Put another way, the market cap rose from around $3 million to close to $3 Billion!
Loyal investors were rewarded once again in 2006, as he was the cofounder of Magnum Uranium, which was taken over by Energy Fuels in 2009. Shareholders were once again exposed to another potential 1000% gain by 2011.